Press release
Masimo Expands Suite of Advanced Measurements Through Acquisition of UK-Based LiDCO Group Plc
Leading Provider of Hemodynamic Monitoring Becomes Masimo Subsidiary IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced that it has
About this update from Masimo Corporation
[{"type":"text","content":"\nLeading Provider of Hemodynamic Monitoring Becomes Masimo Subsidiary \n\n IRVINE, Calif.--(BUSINESS WIRE)--\nMasimo (NASDAQ: MASI) today announced that it has successfully completed the acquisition of the LiDCO Group Plc, a leading provider of advanced hemodynamic monitoring solutions (LiDCO). The Company completed the acquisition of 100% of LiDCO on February 2, 2021.\n\nLiDCO was founded in 1991, launched its first product in 1999, and began trading on the AIM submarket of the London Stock Exchange in 2001. On January 11, 2021, LiDCO was de-listed from AIM and will be re-registered by Masimo as a UK-based private subsidiary.\n\n@Masimo | #Masimo\n\nAbout Masimo\n\nMasimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates3 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.9 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (Sp...